Comparison of the results of the present study with other recent infant AML studies
| Group/study . | Period . | No. of patients . | Treatment . | EFS (%) . | Reference . | ||
|---|---|---|---|---|---|---|---|
| Total . | MLL+ . | MLL− . | |||||
| Japan | 1986 -1998 | 29 | Chemo/SCT | ND | 42 (5 y) | 31 (5 y) | 6 |
| POG (8498) | 1984 - | 523-150 | Chemo | 55 (3 y) | ND | ND | 17 |
| St Jude | 1980 -1994 | 25 | Chemo | ND | 44 (5 y) | 31 (5 y) | 5 |
| (AML80-91) | 1980 -1997 | 28 | Chemo | 32 (5 y) | ND | ND | 7 |
| BFM (AML83, 87) | 1982 -1992 | 1013-150 | Chemo | 34 (5 y) | ND | ND | 8 |
| CCG (2861, 2891) | 1989 -1993 | 44 | Chemo/SCT | ND | 28 (2 y) | 53 (2 y) | 4, 16 |
| MRC (AML10) | 1988 -1995 | 25 | Chemo | 48 (7 y)3-151 | ND | ND | 19 |
| Nordic (NOPHO-84, 88) | 1984 -1992 | 27 | Chemo | 58 (5 y)3-152 | ND | ND | 20 |
| FHCRC | 1974 -1995 | 40 | SCT | 38 (5 y) | ND | ND | 38 |
| Spain | 1990 -1998 | 15 | SCT | 73 (5 y)3-153 | ND | ND | 39 |
| Present study | 1995 -1998 | 35 | Chemo | 72 (3 y) | 74 (3 y) | 73 (3 y) | |
| Group/study . | Period . | No. of patients . | Treatment . | EFS (%) . | Reference . | ||
|---|---|---|---|---|---|---|---|
| Total . | MLL+ . | MLL− . | |||||
| Japan | 1986 -1998 | 29 | Chemo/SCT | ND | 42 (5 y) | 31 (5 y) | 6 |
| POG (8498) | 1984 - | 523-150 | Chemo | 55 (3 y) | ND | ND | 17 |
| St Jude | 1980 -1994 | 25 | Chemo | ND | 44 (5 y) | 31 (5 y) | 5 |
| (AML80-91) | 1980 -1997 | 28 | Chemo | 32 (5 y) | ND | ND | 7 |
| BFM (AML83, 87) | 1982 -1992 | 1013-150 | Chemo | 34 (5 y) | ND | ND | 8 |
| CCG (2861, 2891) | 1989 -1993 | 44 | Chemo/SCT | ND | 28 (2 y) | 53 (2 y) | 4, 16 |
| MRC (AML10) | 1988 -1995 | 25 | Chemo | 48 (7 y)3-151 | ND | ND | 19 |
| Nordic (NOPHO-84, 88) | 1984 -1992 | 27 | Chemo | 58 (5 y)3-152 | ND | ND | 20 |
| FHCRC | 1974 -1995 | 40 | SCT | 38 (5 y) | ND | ND | 38 |
| Spain | 1990 -1998 | 15 | SCT | 73 (5 y)3-153 | ND | ND | 39 |
| Present study | 1995 -1998 | 35 | Chemo | 72 (3 y) | 74 (3 y) | 73 (3 y) | |
Chemo indicates chemotherapy; ND, not described; POG, Pediatric Oncology Group; BFM, Berlin-Frankfurt-Munster; CCG, Children's Cancer Group; MRC, Medical Research Council; FHCRC, Fred Hutchinson Cancer Research Center.
Children aged 1 to 2 years were included.
All children were included.
The figure means the incidence of first CR at 5 years.
The figure means disease-free survival rate at 5 years.